Health Canada Approves Upadacitinib to Treat Adults with PsA

At week 24, minimal disease activity was attained in 25% of patients treated with 15 mg of upadacitinib and 29% of patients treated with 30 mg of upadacitinib compared with 3% of patients treated with placebo.

The most common adverse events reported with upadacitinib were increased levels of serum creatine phosphokinase, alanine transaminases and aspartate transaminases. Nasopharyngitis and upper respiratory tract infection were also reported. No new safety signals were identified.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital. 

References

1. AbbVie. News release: Health Canada approves AbbVie’s Rinvoq (upadacitinib) for the treatment of adults with active psoriatic arthritis. 2021 Jun 7.
2. AbbVie. News release: Rinvoq (upadacitinib) meets primary and key secondary endpoints in phase 3 study in psoriatic arthritis. 2020 Feb 5.
3. AbbVie. News release: Rinvoq (upadacitinib) meets primary and all ranked secondary endpoints in phase 3 study in psoriatic arthritis. 2019 Oct 31.